access

News

Free access to Zolgensma curbed, says Novartis

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company.

Market Access

Nine for 2023, part one: a reflection on inflection

The Roman god Janus, as we are frequently reminded in January, was two faced and able to look forward to the coming year and backward to reflect on the past one.

R&D

6 research and development life science predictions for 2023

From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences tea

News

Achievement-so-far-on-objective-on-affordability

Pharma says VPAS clawback jeopardises UK sector

A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening "footprint, R&D, and manufacturing investments" in the country.

News

Expansion of CareQuest partnership with CIPCOH, funding '100...

The CareQuest Institute for Oral Health, a US non-profit focused on creating a more accessible, equitable, and integrated oral health system – which partnered with the Center for Integratio

Views & Analysis

You get what you agree to, at least when it comes to the mon...

Rising payment percentages under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) have been criticised despite (some in) the industry knowing that payment percentages in

Free access to Zolgensma curbed, says Novartis

Nine for 2023, part one: a reflection on inflection

6 research and development life science predictions for 2023

Pharma says VPAS clawback jeopardises UK sector

Expansion of CareQuest partnership with CIPCOH, funding '100...

You get what you agree to, at least when it comes to the mon...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

access

Editor's Picks